



UNIQUELY NORTHLAND

(TAI TOKERAU PROVINCE)

NZ Tea Tree Agribiz. A NZD1B+ Sunrise Industry

Investment Invitation: NZ Therapeutic Grade Tea Tree Oil Industry Development

USD268B TAM Infection Control Market

ECOSYSTEM PARTNERS
TRIBAL HEALTH CORP (USA)
NZ SHOWCASE (USA) INC (USA)

“EHARA TAKU TOA I TE TOA TAKITAHĪ, HE TOA TAKITINI”

“My strength is not as an individual, but as a Collective”.

INVESTMENT SUBMISSION

For circulation to parties qualifying as Wholesale or Eligible Investors under Schedule 1, Financial
Markets Conduct Act 2013

Northland Therapeutic Tea Tree Oils Industry Development

Submitted by:

Tribal Natural Healthcare Ltd

A Māori economy interfaced, “**Business Combination**” developing Northland’s New Zealand
mānuka and kānuka tea tree sector for the production of gender specific, therapeutic
grade oil for export.

Purpose: To private sector capital to participate in the NZD325k Pre-Series A capital round
supporting the launch of Tribal’s first export order.

Background Image

“Te-Pahi”

Legendary Ngāpuhi Rangatira / Trader / circa 1760-1810

EXECUTIVE OVERVIEW

STRATEGIC CONTEXT

New Zealand’s therapeutic-oil sector is undergoing a major structural change with a unique investor “**vacuum moment**” arising from the collapse of major operators HoneyLab (TRG Pharma) and Manuka Bioscience (MBS) Group. This event has seen national production volumes drop by circa 50%, resulting in **(a)** much lower volumes of mānuka oil and now **(b)**, **no high-volume producers of kānuka oil** operating in New Zealand today. Leaving a huge “vacuum” supply void / opportunity in the marketplace.

- This presents a unique opportunity for Northland to lead **(a)** the **reset** and **(b)** the **rebuilding** of the industry around its abundant natural resource base and respect for Māori land tenure.
- Northland possesses some of the largest contiguous stands of wild tea tree in New Zealand, the majority located on customary Māori land. These resources can be sustainably harvested **without the plantation development costs** that are unavoidably incurred to develop every form of **nonnative plant** based agribiz venture nationwide.

This capex cost avoidance, creating a major **comparative advantage** in term of both **(a)** production economics and **(b)** community participation.

WHY NORTHLAND AND WHY NOW?

This “**vacuum moment**” has created a national supply gap in New Zealand’s therapeutic oil sector that Northland, with its vast areas of wild-growing tea tree biomass and proximity to port infrastructure, **is ideally positioned** to become the new centre of production and export growth. Tribal’s integrated business model — “**from NZ seed to AU value add, to US shelf**” provides a foundation for sustainable regional wealth creation, Māori land utilisation, and high-value export employment.

REGIONAL DEVELOPMENT OUTCOMES

Participation by “Natural Capital” focused investors will directly advance regional-development objectives by:

- **Creating employment** in economically marginalized Māori communities through pruning, plant replacement, pathogen control, harvesting and farm gate delivery.
- **Generating new land-based income streams** for Māori land trusts, incorporations and most importantly, the “*whānau-on-the-whenua*”;



- **Building export capability** and branding Northland as the trusted provenance of NZ tea tree agribiz produced therapeutic healthcare products;
- **Embedding kaitiakitanga** and tikanga-based land stewardship in a modern, export-driven enterprise;
- **Positioning the Far North** as a model of circular, regenerative economic growth.

ABOUT TRIBAL

Tribal is a New Zealand company founded to commercialise the abundant wild tea tree resource growing across Māori-owned lands in the Far North. Unlike plantation-based models, *Tribal's* supply chain relies on naturally regenerating tea tree stands (*kānuka* and *mānuka*), harvested sustainably under tikanga (*customary*) principles. The company operates under a **sustainable, chemical-free harvesting model** designed to preserve biodiversity, protect water quality, and enhance carbon sequestration.

- Seed capital of **NZD1.15M** has already been invested to establish harvesting, extraction, and operational infrastructure. The company is now **fully production-ready**, with an initial **AUD4M supply commitment** from its Australian wholesale distribution partner under a LOI, supported by a NZD240k launch order.

Leadership is anchored by **Luke Shepherd, Chief Executive and Co-Kaitiaki** (*Guardian*), whose family farm in the area was established in 1836. Luke returned from overseas to invest in state-of-the-art extraction technology, ensuring the project blends **intergenerational stewardship** with modern production capability. Working in partnership with the **Lloyd whānau**, whose ancestral lands supply Tribal's launch biomass, provides both **cultural authenticity** and access to thousands of additional hectares of native bushland across the Far North.

EXPRESSION OF INTEREST

Tribal Natural Healthcare Ltd (“Tribal”) seeks strategic expressions of interest from “natural capital” supporting investors in its NZD325,000 Pre-Series A capital round.

This investment will catalyze the first market entry export of New Zealand-origin **kānuka and mānuka therapeutic oils** as part of a “**vacuum moment**” opportunity to establish Northland as the national centre of a potential **NZD1B plus tea tree sunrise agribiz sector**.

Tribal is a “**Business Combination**” operating company headquartered in the Far North. It has raised **NZD 1.15M** by way of seed-capital, establishing harvesting and extraction capacity using wild-grown tea tree biomass located on both Māori and general title lands in the far-north. The company is now **production-ready** and developing a fulfilment



strategy to meet its first export order under an **AUD4M supply commitment** to its Australian wholesale product distribution.

INVESTMENT PURPOSE / USE CAPITAL

The NZD325k Pre-Series A round will:

1. **Scale early production** to fulfil confirmed export orders;
2. **Establish export logistics** and compliance systems for Australia and the USA;
3. **Support TGA / FDA-compliant branding /packaging** under the *Tribal* brand/label.
4. **Provide working capital** to meet contracted supply milestones.

This round bridges to a **NZD6.6M Series A capital raise**, which will fund delivery of full vertical integration from Northland harvesting to international retail distribution through the acquisition of manufacturing / value adding facilities in Australia and a well-established natural health products distribution hub in the United States.

OUR INVITATION

Tribal invites qualifying parties to **jointly subscribe for the NZD325,000 Pre-Series A capital round** on a co-investment basis. Such participation will demonstrate regional confidence in this emerging sector and signal to national agencies and private capital partners that **Northland is committed to leading New Zealand’s next major natural / native products export industry**. Tribal welcomes the opportunity to:

- Present its operational capability and export plan to qualifying parties.
- Outline co-branding and regional-promotion opportunities;
- Discuss investment mechanics and governance participation.

INVESTOR ELIGIBILITY / REGULATORY COMPLIANCE

This Pre-Series A round is open **exclusively to investors who qualify under Schedule 1 of the Financial Markets Conduct Act 2013** (eligible/sophisticated/wholesale investors).

Professional firms are invited to circulate this information to clients who:

- Seek exposure to early-stage export ventures with strong regional and cultural alignment;
- Are interested in primary sector innovation and natural-health product markets;
- Desire a combination of cultural authenticity, environmental stewardship, and economic growth;



- Wish to support the development of a high-value, Māori-economy interfaced agribusiness sector in the Far North.
- Meet the statutory criteria for wholesale/eligible investment under the FMC Act.

Information memoranda and detailed investment documentation are available on request to verified eligible investors.

DISCLAIMER:

This document is distributed for informational purposes only to eligible investor parties under Schedule 1 of the Financial Markets Conduct Act 2013. It does not constitute a public offer or solicitation

CONTACT: Tribal Natural Healthcare Ltd
Website: <https://tribalteatree.com>

Luke Shepherd NZ Ops director – Chief Executive – Co-Kaitiaki
Email: luke@tribalteatree.health
Mobile +64-21-024 289754

Eric Lloyd Biomass supply Director -Māori landowner liaison – Co-Kaitiaki
Email: harvest@tribalteatree.health
Mobile +64-21-132 7185

Nic Iverson Export Development Director
Email: nic@tribalteatree.health
Mobile +64-21-178 7637

Linda Brink US Operations Director
Email: linda@tribalteatree.health
Mobile +1-954-203 6233

OUR LAUNCH PHASE DEVELOPMENT TEAM

For a “NATURAL CAPITAL” investment korero.

“Natural Capital” the natural resources and environmental features in a given area, regarded as having economic value or providing a service to humankind”.

The Tribal Investment Objective

Investors

“To build a profitable, integrated, value added *Seed-to-Ship* production supply chain in NZ and AU, seamlessly interfaced with *Ship-to-Shelf* distribution in the US and other markets”.

Grower-Producers

“To deliver recurring annual income and wealth creation through long term supply contracts supporting regenerative agribiz ventures in rural communities.

Luke Shepherd
CEO – NZ Ops Director



Eric Lloyd
Biomass Ops Director



Nicholas Iverson
AU Ops Director



Linda Brink
US Ops Director



Shona Hammond Boys

Community Outreach



John Cilliers CPA

SX Advisory



NZ project support office +64-9-945 6927
PO Box 80, Kerikeri 0245, New Zealand.

<https://tribalteatree.com>

<https://investnz.us>


EXHIBIT

“FAR NORTH TERPENE ” V “OUT EAST TRIKETONE”

“Would a natural health conscious consumer, want to use a plant oil that has a naturally occurring, but toxic herbicide compound in its chemical composition?”

(i.e., a herbicide that has been synthesized for agricultural sprays. For many consumers, application dependent!)


HIGH TERPENE CHEMOTYPE V HIGH LEPTOSPERMONE



Leptospermone is a chemical compound (a **β -triketone**) that was first identified in the US in 1977 when a Stouffer chemical company research chemist noted that the compound “leptospermone” produced by some members of the myrtle family (*Myrtaceae*), such as *Callistemon citrinus* (*Lemon Bottlebrush*), a shrub native to Australia, and *Leptospermum Scoparium* (*Mānuka*, the NZ tree from which it gets its name) produced a natural “herbicide” that killed off invading plant species. Leptospermone was subsequently optimized

into thousands of compounds. Research noted that several were found to be extremely effective **but were too toxic**, environmentally persistent or not selective enough.

There are now several members of the **triketone class of HPPD inhibitor herbicides** on the market produced from a synthesized form of Leptospermone. The same chemical compound that some mānuka oil producers and retailers in NZ use to support their claim that the higher the triketone content, the more efficacious the oil as a malicious pathogen inhibitor for human application. Ongoing research suggests that this appears to be an inappropriately interpretive, non-registrable therapeutic claim. One that a regulatory authority is unlikely to approve for therapeutic product claim registration in the US.



Conversely, **Terpenes** have been found to be highly effective with excellent antifungal, antimicrobial and anti-inflammatory actives that are therapeutically beneficial for human application. Both as topical and ingestible remedies. A fact proven by the native peoples of Aotearoa and the early European arrivals in NZ such as Captain Cook as discussed above. Interestingly, the Australian standard for their tea-tree oil requires a high terpene-based content in the oil (*terpinen-4-ol*) with a low cineole (*toxic*) content.

Based on the Australian standard, one could conclude that mānuka & kānuka oil from Northland would be safe for personal use because of the extremely low levels of triketone, a known toxin. The collective terpene isoprene constituents in manuka & kanuka oil represent the trusted gold standard of care while triketone counts indicate the level of a toxic active in the oil. Having been an investor & working participant in the Australian tea tree oil sector for nearly 10 years,

Having been involved in **(1)** growing and harvesting the oil in the Bungawalbyn Valley, **(2)** developing consumer products and **(3)** worked with the TGA process in Australia, the directors have learnt one key issue, **(4) the research must never end.**